Search
faricimab-svoa (Vabysmo)
Indications:
- treatment of:
- age-related macular degeneration
- macular edema
- diabetic macular edema
- macular edema due to retinal vein occlusion
Adverse effects:
- risk of transient increases in intraocular pressure, endophthalmitis, & retinal detachment
- low risk of arterial thromboembolism
Pharmacokinetics:
- expected to be catabolized like endogenous immunoglobulin
- appparent systemic 1/2 life of 7.5 days
Mechanism of action:
- IgG1-based dual specific antibody against VEGF-A & Ang-2
- suppresses endothelial proliferation, neovascularization, & vascular permeability
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
ophthalmic agent (eyedrops)
References
- DrugBank Online
https://go.drugbank.com/drugs/DB15303
- Hutton D
Studies: Faricimab improved and maintained vision for patients with wet AMD, DME.
Ophthalmology Times. 2022. Jan 24
https://www.ophthalmologytimes.com/view/studies-faricimab-improved-and-maintained-vision-for-patients-with-wet-amd-dme
- Sharma A, Kumar N, Parachuri N et al
Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI)
regime for future DME trial.
Eye 2021. Aug 15
https://www.nature.com/articles/s41433-021-01831-4
- Wikipedia: Faricimab
https://en.wikipedia.org/wiki/Faricimab